Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. - Wikidata - awgldk - TriplyDB

Neurovascular and neuroimmune aspects in the pathophysiology of rosacea.

Neurovascular and neuroimmune aspects in the pathophysiology of rosacea.

http://www.wikidata.org/entity/Q36992055

about

The role of brimonidine tartrate gel in the treatment of rosacea Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition Skin barrier in rosacea Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments Multidisciplinary Consideration of Potential Pathophysiologic Mechanisms of Paradoxical Erythema with Topical Brimonidine Therapy Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features [Dermatological diseases and their importance for psychiatry].Recent advances in the understanding and management of rosacea.Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea Rosacea: new and emerging treatments.Management of cutaneous rosacea: emphasis on new medical therapies.A study on the epidemiology of rosacea in the U.K.Altered manifestations of skin disease at sites affected by neurological deficit.Comparative efficacy of intense pulsed light for different erythema associated with rosacea.Augmented supraorbital skin sympathetic nerve activity responses to symptom trigger events in rosacea patients.Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea.Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema Prospective Comparison of Dual Wavelength Long-Pulsed 755-nm Alexandrite/1,064-nm Neodymium:Yttrium-Aluminum-Garnet Laser versus 585-nm Pulsed Dye Laser Treatment for Rosacea.Dermasence refining gel modulates pathogenetic factors of rosacea in vitro.Corneal and conjunctival sensitivity in rosacea patients.Clinical, cellular, and molecular aspects in the pathophysiology of rosacea.Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit Skin disorders in Parkinson's disease: potential biomarkers and risk factors.Proteases and proteomics: cutting to the core of human skin pathologies.Facial dystonias and rosacea: is there an association?Endoplasmic reticulum stress: key promoter of rosacea pathogenesis.Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics.Friends or Foes? Host defense (antimicrobial) peptides and proteins in human skin diseases.Rosacea and gastrointestinal disorders: a population-based cohort study.Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models.Topical a-Agonist Therapy for Persistent Facial Erythema of Rosacea and the Addition of Oxmetazoline to the Treatment Armamentarium: Where Are We Now?The association between psychiatric diseases, psychotropic drugs and the risk of incident rosacea.Antihypertensive drugs and the risk of incident rosacea.An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes.[Current insights into the pathophysiology of rosacea].Rosacea, the face of innate immunity.Quality of life among patients with rosacea: an investigation of patients in China using two structured questionnaires.

P2860

Q26777249-B667A3BD-5F85-496F-83BE-51AC52AD7052 Q28067747-51F1B834-5942-4DA6-AAF1-38DB4D7DCF90 Q28069342-7C735E50-870E-4CAC-B8AC-C826F8BE8B03 Q28072685-DA8A2265-136D-45F3-B65E-92D5F9D9433D Q28077384-D1C7886C-C9B8-49CA-A872-06EA1DA2592D Q28077479-BAB41A6E-A044-4F00-8247-5ECE508BF7EE Q30251786-906A5906-8EBD-4A8D-A30E-4DFE1B972B1A Q33942083-E45D096C-4243-4E2C-A85B-F250FF990990 Q34353391-289E7C17-84DC-4433-AE11-8862946355B5 Q34434971-13FFEE7C-21C8-4704-82BE-09F101712524 Q34436744-54C7BCAB-0AB5-43C2-8C1E-43430C4EC1C4 Q34638049-47D952A3-4F94-4110-B43D-2D982E49954D Q35079603-68E31ACC-89BF-47E7-A8E7-186522195F5B Q35230579-F798A4A7-CB4D-4CE1-AB10-32F860B887CA Q35680501-D48AACED-D624-4D57-B853-D741C795D768 Q35834762-5ADA70B2-EC8F-4083-922E-B640371487B1 Q35862102-0E93B713-FFB5-4AB0-98B3-03254B1E2E3F Q35862114-CF55B578-0761-4CD0-9E74-FB135FB86BC6 Q36164626-DDC4DE97-87CC-4CE7-9D11-6235DBDA6ED4 Q36325038-38F78BC0-1470-4AFA-BAEC-FF854ABD54BE Q36595369-862D82B3-692A-4511-BF94-F794102F7701 Q36991412-1C9AD716-4511-44A8-A92F-6EC3880AAF51 Q37013298-F0D39422-E0D8-4FD1-83B9-70C5AE5A94E6 Q37595472-B4CB34A6-8D78-47B8-B582-240F5EBEAC7B Q37702287-09C8DBB4-A5F9-4DC1-AE7C-524772966B5B Q38200069-DA90C3CC-A245-4E7E-97B8-68EEFDDB479A Q38212027-9AA1978D-50E0-4CC8-9672-0A3DB259DB00 Q38232251-85D1F6B0-FD0F-4068-89DD-58808E35DB1F Q38236823-759DEB2E-3DE0-47B6-9D70-EC384191426A Q38885566-7028956E-1B70-4D6E-BDD1-85A66F34F603 Q39133115-1B006050-2E57-4363-A893-58C6C2143C10 Q39512887-05A2F88B-81FB-4D8A-9F59-81A38FC8C262 Q42230578-93941467-F320-4AC5-891C-32C3F963C2B6 Q43379739-18AFF0A3-80B7-424E-92F6-55EB3C95D9A8 Q43793565-29F4D312-AA27-4C9F-BFA0-177236244548 Q44804086-5212122E-60F2-47E4-AC37-DFFCBCB71027 Q45153232-D127FCCE-6366-45F7-BD4C-48D69B99FA9C Q46276685-599B916B-85F3-4B16-96E1-50D3B5450743 Q46464886-33AF769F-81A8-4129-9355-7EE2B0FCEE8E Q47641618-1EBDDEE9-4EEB-4691-A600-294C749E6BD1

P2860

Neurovascular and neuroimmune aspects in the pathophysiology of rosacea.

http://www.wikidata.org/entity/Q36992055

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Neurovascular and neuroimmune aspects in the pathophysiology of rosacea.

@en

type

label

Neurovascular and neuroimmune aspects in the pathophysiology of rosacea.

@en

prefLabel

Neurovascular and neuroimmune aspects in the pathophysiology of rosacea.

@en

P1433

Q36992055-AAA091E2-7583-41B6-8A79-89126D7BA5A7

P1476

Q36992055-4548920E-B772-4EFD-8495-C018A1668AE7

P2093

Q36992055-014663DA-3B35-4716-BA37-D96950317890

Q36992055-08430130-A4A8-4446-8ADF-B93C7EE9287C

Q36992055-1F98CDBB-C451-47F1-94D8-9A4DF790AB6D

Q36992055-235F6607-AFA5-46A1-B250-C31625419649

Q36992055-5A919463-600B-455B-942B-4A618550A7E9

Q36992055-62241830-BCD8-40B6-A639-710F0BF37882

Q36992055-65C8A996-8700-47A8-A9D0-F1EDE569E91F

Q36992055-7DE7BD09-4AC0-403A-AE54-3762B0F8D62A

Q36992055-9A727141-0D37-4087-B7F0-ED36A18D33B7

Q36992055-9FA79679-A03C-4959-BF29-45A128C64435

P2860

Q36992055-021C29F3-368C-439C-BB62-A194CA2789BB

Q36992055-0728E78B-43C9-4C45-99AF-C47A17E6A4F9

Q36992055-0EEE840C-7D15-4FDC-BF72-2F12D9EF2806

Q36992055-1A54D654-0626-4146-BAAB-D344FEDECDB8

Q36992055-23C420CE-7AB2-4619-A1D5-FFDC514D9967

Q36992055-243F1EF6-7210-497F-BDAE-E7A1D2D5FE00

Q36992055-267F6BE0-E288-4FEF-AB1F-BDABA3B2C8DB

Q36992055-26EF9628-40DE-40A1-A4BC-0CCC2340275F

Q36992055-28996425-99DD-4562-977F-F14FAEBE7125

Q36992055-291F77A4-957D-4EC5-BFA7-9E55CEBDAFFB

P2888

Q36992055-109C844A-2354-48A1-84A4-867448ED6963

P304

Q36992055-73386480-4916-43F4-92A1-16F8EB046321

P31

Q36992055-2BE38233-9146-4313-AD4D-CC491280C8B9

P356

Q36992055-CC8C1553-72E7-403B-8A46-B1CAD333783A

P433

Q36992055-65C7140D-9168-457B-A72E-5D90920C6EBB

P478

Q36992055-46A80AE4-C2C8-4755-85A3-71C57766762F

P577

Q36992055-45C81277-556F-4368-BE5A-4D91FB0A42E5

P5875

Q36992055-3B1FE817-EA3C-4725-AE91-8E3D196D0194

P6179

Q36992055-70669CAC-5211-47B9-B35F-E283CC69B60D

P698

Q36992055-5417D090-59D0-4F0E-BCD6-2D55DE5DB944

P921

Q36992055-BB68E253-119B-453C-9D7F-C4BBBF4D5BC6

P932

Q36992055-92ACC2FF-3097-4F65-AB6B-C0AB148A244A

P356

P1433

The journal of investigative dermatology. the Society for Investigative Dermatology, Inc. [and] European Society for Dermatological Research. Symposium proceedings /

P1476

Neurovascular and neuroimmune aspects in the pathophysiology of rosacea.

@en

P2093

Christian Mess

http://www.w3.org/2001/XMLSchema#string

Dieter Metze

http://www.w3.org/2001/XMLSchema#string

Ferda Cevikbas

http://www.w3.org/2001/XMLSchema#string

Isabelle Carlavan

http://www.w3.org/2001/XMLSchema#string

Jerome Aubert

http://www.w3.org/2001/XMLSchema#string

Johannes J Voegel

http://www.w3.org/2001/XMLSchema#string

Jörg Buddenkotte

http://www.w3.org/2001/XMLSchema#string

Martin Steinhoff

http://www.w3.org/2001/XMLSchema#string

Mathias Sulk

http://www.w3.org/2001/XMLSchema#string

Michel Rivier

http://www.w3.org/2001/XMLSchema#string

P2860

Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea

The neurobiology of itch

[Rosacea 2009 : new advances in pathophysiology, clinical staging and therapeutic strategies].

Laser treatment of rosacea: a pathoetiological study.

Mite-related bacterial antigens stimulate inflammatory cells in rosacea.

Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea.

PACAP and VIP differentially preserve neurovascular reactivity after global cerebral ischemia in newborn pigs.

Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: expression of PACAP-38 is increased in patients with psoriasis.

Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation.

Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo.

P2888

P304

53-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JIDSYMP.2011.6

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51792111

http://www.w3.org/2001/XMLSchema#string

P6179

1045753458

http://www.w3.org/2001/XMLSchema#string

P698

22076328

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology

P932

3704331

http://www.w3.org/2001/XMLSchema#string